

IN THE CLAIMS:

1-20. (Cancelled)

21. (Currently amended) A pharmaceutical composition comprising the antibody of any one of Claims ~~29-33~~ 29-31 or 33-34.

22-28. (Cancelled)

29. (Previously presented) An antibody directed against an isolated IL-16 antagonist peptide consisting of CLLS (SEQ ID NO:2).

30. (Previously presented) An antibody directed against an isolated IL-16 antagonist peptide consisting of any one of WQCLLS (SEQ ID NO:4), WQALLS (SEQ ID NO:5), VVQVVA (SEQ ID NO:9) or VKQVVA (SEQ ID NO:11).

31. (Previously presented) An antibody directed against an isolated IL-16 antagonist peptide consisting of GMWQCLLS (SEQ ID NO:13).

32. (Canceled)

33. (Previously presented) An antibody directed against an isolated IL-16 antagonist peptide consisting of TGLWQCLLSEGD (SEQ ID NO:14).

34. (Previously presented) An antibody directed against an isolated IL-16 antagonist peptide consisting of VSEEQKVQVVA (SEQ ID NO:15).

35. (Cancelled)